Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
BoD
Rolf Stahel has been the Chairman of the Board since 2004.Mr. Stahel, a Swiss national, has a degree in Business Studies from Kantonsschule Lucerne, Switzerland, and has attended the Advanced Management Programme at Harvard Business School.
Luca Benatti, the Company's Managing Director and Chief Executive Officer since 1998, founded Newron in 1998 along with Dr. Ruggero Fariello and Dr. Patricia Salvati.
Francesco Parenti, a Director since 1999, holds a Ph.D. in biological sciences from the University of Milan and has conducted post doctoral research at Yale University.
Patrick Langlois, a director since April 2008, was the CFO and Vice-Chairman of the Management Board of Aventis from 2002 to 2005 and served for 30 years in various senior financial functions in Rhone-Poulenc and Aventis Group in France and the USA.
Hanns Moehler, a director since April 2008, is Vice-Director of the Swiss National Center of Neuroscience Research, of which he was the first director from 2000 to 2004.